Is Semaglutide Safe to Take for Years? What 5+ Years of Trial Data Actually Shows

The Question Nobody Asked Five Years Ago

When semaglutide first hit pharmacy shelves, everyone wanted to know one thing: does it work? Now, millions of prescriptions later, the question has shifted. People aren't wondering if they'll lose weight anymore. They're wondering what happens to their bodies after taking this medication for five, ten, maybe fifteen years.

It's a fair concern. We've been burned before. Remember fen-phen? That weight loss combination seemed miraculous until heart valve damage started showing up years later. So when your doctor suggests staying on semaglutide indefinitely, you deserve more than reassurance. You deserve data.

Good news: we finally have some. The SELECT trial's extended follow-up published in late 2024, combined with a comprehensive meta-analysis from The Lancet in early 2025, gives us our first real window into what long-term GLP-1 use looks like. Let's dig into what 17,604 participants taught us over five years.

What the SELECT Trial Actually Found After 5 Years

The SELECT trial wasn't designed to study weight loss. It enrolled people with existing cardiovascular disease or high cardiovascular risk—the kind of patients whose doctors lose sleep worrying about heart attacks. Half got semaglutide. Half got placebo. Then researchers watched and waited.

After a mean follow-up of 39.8 months (with many participants now past the five-year mark in extended observation), the results were striking. Semaglutide reduced major adverse cardiovascular events—heart attacks, strokes, and cardiovascular death—by 20%. That's not a small number. For context, statins, which we consider foundational heart medications, typically reduce events by 25-35%.

But here's what matters for the safety conversation: the trial also tracked every side effect, every hospitalization, every concerning lab value. And the picture that emerged was more nuanced than either enthusiasts or skeptics expected.

Gastrointestinal issues remained the most common complaint. About 10% of participants experienced nausea significant enough to mention, though this typically faded after 8-12 weeks. Serious GI events requiring hospitalization occurred in 1.6% of the semaglutide group versus 1.1% on placebo. Not nothing, but not alarming either.

The Muscle Mass Question Gets Real Answers

If you've spent any time in weight loss communities, you've heard the worry: "Sure, you lose fat, but you're also losing muscle." This concern isn't unfounded. Early studies showed that roughly 25-40% of weight lost on GLP-1 medications came from lean mass rather than fat.

The 2025 Lancet meta-analysis tackled this head-on, pooling data from 28 trials with follow-up periods ranging from 6 months to 5 years. Their findings? Lean mass loss does occur, but it follows a pattern. During the first year, when weight loss is most rapid, lean mass drops alongside fat mass. By years two through five, the ratio stabilizes. Participants who maintained consistent protein intake (at least 1.2g per kilogram of body weight daily) and engaged in resistance training lost significantly less muscle.

One subset analysis caught my attention. Among participants over 65, those who combined semaglutide with twice-weekly resistance training retained 78% of their baseline lean mass after three years. Those who didn't exercise retained only 61%. The medication isn't the whole story—what you do alongside it matters enormously.

Thyroid Concerns: Separating Signal from Noise

Every semaglutide package carries a black box warning about thyroid C-cell tumors. This warning exists because rodent studies showed increased thyroid cancer risk. But rodent thyroid biology differs substantially from human thyroid biology. So what do five years of human data tell us?

The SELECT trial recorded 12 cases of thyroid cancer in the semaglutide group and 8 in the placebo group. Statistically, this difference wasn't significant—it could easily be chance. The Lancet meta-analysis, with its larger pooled population, found a relative risk of 1.14 for thyroid malignancies. In plain English: a possible small increase that researchers couldn't confirm was real.

For people with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, the calculus is different. These conditions remain absolute contraindications. But for the general population, five years of surveillance hasn't revealed the thyroid cancer signal that some feared.

Gallbladder Disease: The Underappreciated Risk

Here's something that doesn't get enough attention: gallbladder problems. Rapid weight loss has always increased gallstone risk—this isn't unique to GLP-1 medications. But the SELECT data showed gallbladder-related adverse events in 2.8% of semaglutide participants versus 2.3% on placebo.

That gap widened among participants who lost weight most quickly. Those who dropped more than 15% of body weight in the first year had gallbladder event rates approaching 4.5%. The mechanism makes sense: when you lose fat rapidly, your liver dumps more cholesterol into bile, which can crystallize into stones.

Some clinicians now recommend ursodeoxycholic acid (a bile acid medication) for patients losing weight rapidly on GLP-1s, though this isn't yet standard practice. At minimum, knowing the symptoms of gallbladder disease—right upper abdominal pain, especially after fatty meals—seems prudent for anyone on long-term therapy.

Kidney Function Over Time

The kidney story is actually encouraging. GLP-1 receptor agonists appear to have protective effects on kidney function, separate from their weight loss benefits. The FLOW trial (completed in 2024) specifically examined kidney outcomes in people with type 2 diabetes and chronic kidney disease.

After a median follow-up of 3.4 years, semaglutide reduced the risk of kidney function decline by 24%. Participants were less likely to need dialysis, less likely to experience doubling of serum creatinine, and less likely to die from kidney-related causes.

For people without existing kidney disease, the SELECT trial showed stable kidney function over five years. No unexpected signals emerged. This doesn't mean monitoring isn't warranted—annual kidney function tests remain reasonable—but the data so far suggests kidneys tolerate long-term GLP-1 exposure well.

Mental Health: The Complicated Picture

In 2023, European regulators briefly investigated reports of suicidal thoughts among GLP-1 users. The SELECT trial's mental health data, now available through extended follow-up, provides important context.

Depression and anxiety rates didn't differ significantly between semaglutide and placebo groups. If anything, participants on semaglutide reported slightly improved mental health scores at years three and four—possibly related to improved physical health, weight loss satisfaction, or reduced cardiovascular anxiety.

However, the trial excluded people with active severe depression or recent suicidal ideation. So we can't extrapolate these findings to everyone. What we can say: in a population without pre-existing severe mental illness, five years of semaglutide didn't increase psychiatric adverse events.

Anecdotally, some users report feeling "flat" or experiencing reduced food-related pleasure. This isn't captured well in clinical trial endpoints. It's worth discussing with your healthcare provider if you notice mood changes, even subtle ones.

What Happens When You Stop?

The STEP 4 trial extension and subsequent real-world analyses paint a consistent picture: most people regain weight after stopping semaglutide. In STEP 4, participants who switched from semaglutide to placebo after 20 weeks regained about two-thirds of lost weight within a year.

This isn't a failure of the medication. It reflects biology. Obesity involves persistent changes in hunger hormones, metabolic rate, and brain reward circuitry. When you remove the medication that was helping regulate these systems, the underlying drivers of weight gain remain.

Some researchers now frame GLP-1 medications like blood pressure medications or statins—tools for managing chronic conditions rather than short-term fixes. Whether that framing is appropriate remains debated, but it does align with what the data shows about weight regain after discontinuation.

Making Sense of Five Years of Evidence

So, is semaglutide safe to take for years? The honest answer is: safer than we had any right to expect, with caveats.

The cardiovascular benefits are real and substantial. A 20% reduction in heart attacks and strokes isn't trivial—for high-risk patients, this rivals the benefit of medications we've used for decades. Kidney protection appears genuine. The thyroid cancer fears, while not completely dismissed, haven't materialized into clear human risk.

The trade-offs are also real. Gastrointestinal side effects bother some people indefinitely. Muscle loss requires active countermeasures. Gallbladder disease risk increases, especially with rapid weight loss. And we still don't know what fifteen or twenty years of use looks like.

The Lancet meta-analysis concluded with unusual directness for an academic paper: "Available evidence supports the cardiovascular safety and potential benefit of GLP-1 receptor agonists over medium-term use, while acknowledging that longer surveillance remains necessary."

That's about as confident as medical science gets. Five years of data from thousands of participants tells us a lot. It doesn't tell us everything. For now, the evidence suggests that for most people, the benefits of long-term semaglutide use outweigh the known risks—especially when combined with lifestyle measures that protect muscle mass and when monitored appropriately for emerging concerns.